依普利酮何时在中国上市？

When will it be launched in China? Eplerenone (Inspra) is an oral drug with definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It was first approved for marketing in the United States in 2002. It has not yet been officially launched in China, and the specific launch time is temporarily unknown.

In recent years, more and more evidence has shown that other tissues, especially the brain, heart and blood vessels, can also independently synthesize aldosterone. Not only that, it can also directly affect blood pressure, damage the heart, brain, kidneys and other organs, seriously affecting the patient's health. Eplerenone (Inspra) is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. It has fewer side effects. In treating patients with stage 1 and 2 hypertension, eplerenone has similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril.

Eplerenone (Inspra) is administered orally and can be used alone or in combination with other drugs related to the treatment of hypertension. The recommended dose for adults is an initial dose of 50 mg, once a day. The maintenance dose is 50mg, 1-2 times a day. Maximum dose: 100 mg/day. If the patient does not respond adequately to the initial dose during treatment, it can be increased to 50 mg twice daily.

Although it is not yet on the market in my country, India has launched the lower-priced eplerenone (Inspra). The effect is basically the same as the original drug in the United States. The specification is 50mg*100 tablets and the price is about $500. Due to the influence of exchange rates and other factors, the price is not fixed. If you have a purchase need but it is inconvenient to go abroad, you can consult the medical companion travel service for specific information.